Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening

被引:78
作者
Jauregui-Amezaga, Aranzazu [1 ]
Turon, Fanny [1 ]
Ordas, Ingrid [1 ]
Gallego, Marta [1 ]
Feu, Faust [1 ]
Ricart, Elena [1 ]
Panes, Julian [1 ]
机构
[1] Hosp Clin Barcelona, Deparment Gastroenterol, CIBER EHD, E-08036 Barcelona, Spain
关键词
Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Infliximab; Adalimumab; Tuberculosis; TUMOR-NECROSIS-FACTOR; INFLAMMATORY-BOWEL-DISEASE; GAMMA RELEASE ASSAY; CROHNS-DISEASE; MYCOBACTERIUM-TUBERCULOSIS; MAINTENANCE THERAPY; SKIN-TEST; INFLIXIMAB; PERFORMANCE; ADALIMUMAB;
D O I
10.1016/j.crohns.2012.05.012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: In patients treated with TNF-antagonists, incident cases of tuberculosis (TB) after a negative screening have been reported, leading to the suggestion that improved TB testing is necessary. Aim: The aim of the current study is to establish the incidence of TB and its characteristics in patients with inflammatory bowel disease (IBD) under TNF antagonists to design improved prevention strategies. Methods: IBD patients from a single center treated with anti-TNF therapy between January 2000 and September 2011 were identified through a database that prospectively records clinical data, treatments and adverse events. Results: During the study period 423 patients received anti-TNF therapy. Screening for latent TB infection (LTBI) previous to anti-TNF treatment was positive in 30 patients (6.96%). Seven patients (1.65%) developed TB while under anti-TNF treatment. Six patients (five under imnnunosuppressant treatment) had a negative LTBI screening. TST was positive in one patient not receiving immunosuppressants, and was treated with isoniazid before starting anti-TNF therapy. In 4 patients TB was diagnosed within the first 16 weeks after starting anti-TNF therapy. Three cases had pulmonary TB and 4 extrapulmonary disease. Conclusions: In the IBD population under study, incidence of TB infection associated with anti-TNF therapy is higher than that reported in controlled trials and occurs early after treatment initiation. False negative results of LTBI despite appropriate measures may occur, suggesting that more effective screening strategies are needed. (C) 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:208 / 212
页数:5
相关论文
共 32 条
[21]   Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases:: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay [J].
Matulis, G. ;
Jueni, P. ;
Villiger, P. M. ;
Gadola, S. D. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (01) :84-90
[22]  
Obrador A, 2003, Gastroenterol Hepatol, V26, P29, DOI 10.1157/13042212
[23]   Factors Impacting the Results of Interferon-γ Release Assay and Tuberculin Skin Test in Routine Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Diseases [J].
Papay, Pavol ;
Eser, Alexander ;
Winkler, Stefan ;
Frantal, Sophie ;
Primas, Christian ;
Miehsler, Wolfgang ;
Novacek, Gottfried ;
Vogelsang, Harald ;
Dejaco, Clemens ;
Reinisch, Walter .
INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) :84-90
[24]   QuantiFERON TB Gold Testing for Tuberculosis Screening in an Inflammatory Bowel Disease Cohort in the United States [J].
Qumseya, Bashar J. ;
Ananthakrishnan, Ashwin N. ;
Skaros, Sue ;
Bonner, Michael ;
Issa, Mazen ;
Zadvornova, Yelena ;
Naik, Amar ;
Perera, Lilani ;
Binion, David G. .
INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) :77-83
[25]   European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease [J].
Rahier, J. F. ;
Ben-Horin, S. ;
Chowers, Y. ;
Conlon, C. ;
De Munter, P. ;
D'Haens, G. ;
Domenech, E. ;
Eliakim, R. ;
Eser, A. ;
Frater, J. ;
Gassull, M. ;
Giladi, M. ;
Kaser, A. ;
Lemann, M. ;
Moreels, T. ;
Moschen, A. ;
Pollok, R. ;
Reinisch, W. ;
Schunter, M. ;
Stange, E. F. ;
Tilg, H. ;
Van Assche, G. ;
Viget, N. ;
Vucelic, B. ;
Walsh, A. ;
Weiss, G. ;
Yazdanpanah, Y. ;
Zabana, Y. ;
Travis, S. P. L. ;
Colombel, J. F. .
JOURNAL OF CROHNS & COLITIS, 2009, 3 (02) :47-91
[26]   Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients [J].
Richeldi, Luca ;
Losi, Monica ;
D'Amico, Roberto ;
Luppi, Mario ;
Ferrari, Angela ;
Mussini, Cristina ;
Codeluppi, Mauro ;
Cocchi, Stefania ;
Prati, Francesca ;
Paci, Valentina ;
Meacci, Marisa ;
Meccugni, Barbara ;
Rumpianesi, Fabio ;
Roversi, Pietro ;
Cerri, Stefania ;
Luppi, Fabrizio ;
Ferrara, Giovanni ;
Latorre, Irene ;
Gerunda, Giorgio E. ;
Torelli, Giuseppe ;
Esposito, Roberto ;
Fabbri, Leonardo M. .
CHEST, 2009, 136 (01) :198-204
[27]   TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection [J].
Roach, DR ;
Bean, AGD ;
Demangel, C ;
France, MP ;
Briscoe, H ;
Britton, WJ .
JOURNAL OF IMMUNOLOGY, 2002, 168 (09) :4620-4627
[28]   Infliximab for induction and maintenance therapy for ulcerative colitis [J].
Rutgeerts, P ;
Sandborn, WJ ;
Feagan, BG ;
Reinisch, W ;
Olson, A ;
Johanns, J ;
Travers, S ;
Rachmilewitz, D ;
Hanauer, SB ;
Lichtenstein, GR ;
de Villiers, WJS ;
Present, D ;
Sands, BE ;
Colombel, JF .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2462-2476
[29]   Infliximab maintenance therapy for fistulizing Crohn's disease [J].
Sands, BE ;
Anderson, FH ;
Bernstein, CN ;
Chey, WY ;
Feagan, BG ;
Fedorak, RN ;
Kamm, MA ;
Korzenik, JR ;
Lashner, BA ;
Onken, JE ;
Rachmilewitz, D ;
Rutgeerts, P ;
Wild, G ;
Wolf, DC ;
Marsters, PA ;
Travers, SB ;
Blank, MA ;
van Deventer, SJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (09) :876-885
[30]   Comparison of Interferon-Gamma Release Assay Versus Tuberculin Skin Test for Tuberculosis Screening in Inflammatory Bowel Disease [J].
Schoepfer, Alain M. ;
Flogerzi, Beatrice ;
Fallegger, Silvia ;
Schaffer, Thomas ;
Mueller, Stefan ;
Nicod, Laurent ;
Seibold, Frank .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (11) :2799-2806